Views
4 years ago

C7 - E Zaidel - 12/2015

  • Text
  • Nitroxilos
  • Calcio
  • Angiotensina
  • Sraa
  • Adrenergico
  • Cardiovascular
  • Miocardio
  • Nivel
  • Beta
  • Mecanismos
  • Ventricular
  • Aumento
  • Efecto
  • Insuficiencia
  • Calcio
  • Cardiaca
Mecanismos biológicos y adaptativos del miocardio en la insuficiencia cardiaca con disfunción ventricular y su modulación farmacológica

EM Ylarri //

EM Ylarri // Farmacología cardiovascular. De la molécula al paciente. Bases biológicas y targets en la terapéutica cardiovascular Lectura sugerida • McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ. 1993;6:91-8. • McMurray J, Adamopoulos S, Anker S, et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. EurHeart J. 2012;33:1707-1847. • Corradi L, Perez G, Costabel J, et al. Insuficiencia cardiaca descompensada en Argentina: Registro CONAREC XVIII. Rev Argent Cardiol 2014;82:529-38. • Jessup M, Brozena S. Heart Failure. New Engl JMed. 2003;348:2007-2018. • Zannad F, García A, Anker S, et al. Clinical outcome endpoints in heart failure trials. An ESC heart failure association consensus document. Eur J HeartFail. 2013;15:1082-94. • Lymperopoulos A, Rengo G, Kock W. Adrenergic nervous system in heart failure. Circ Res. 2013;113:739-53. • Jahns R, Boivin V, Siegmund C. Autoantibodies activating human B1 Adrenergic receptors are associated with reduced Cardiac function in chronic heart failure. Circulation.1999;99:649-54. • Goldsmit S. The role of vassopresin in heart failure. ClevClin J Med. 2006;73:19-23. • Unger T, Li J. The role of the rennin angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5:7-10. • Schrier R. Aldosterone “escape” vs. “breakthrough”. Nat Rev Nephrology. 2010;6:61. • Parker J, Thiessen J. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol. 2004;286:1141-4. • Almenar Bonet L, Martínez-Dotz L. Natriuretic peptides in heart failure. RevEspCardiol. 2006;6:15-26. • Erdman E, Shwinger R, Beuckelmann D, etal. Altered calcium homeostasis in chronic heart failure. Z Cardiol 1996;85:123-28. • Goldhaber J, Hamilton. Role of inotropic agents in the treatment of heart failure. • Uneger M, Boivin V, Hans-Peter et al. First administration of COR-1 in Man. Circulation. 2010;122:197-30. • Rahimtoola S. Digoxin therapy for patients in clinical heart failure. 2004;102:2942-6. • Ferrandi M, Barassi P, Tadini F. Istaroxine stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Brit J Pharmacol. 2013;169:1849-61. vLee J, Allen D. Calcium sensitisers: mechanisms of action and potential usefulness as inotropes. Cardiovasc Res. 1997;36:10-20. • Malik F, Hartman J, Morgan D, et al.Cardiac myosin activation: A potential target forheartfailure. Science. 2011;331:1439-43. • Arcaro A, Lembo G, Tocchetti C. Nitroxyl(HNO) for treatment of heart failure. CurrHeart Fail Rep. 2014;11:227-35. 106

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015